Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes

European Journal of Endocrinology

Volumn 155, Issue 4, 2006, Pages 615-622

  Shim, Wan Sub ^a   Kim, Soo Kyung ^c   Kim, Hae Jin ^d   Kang, Eun Seok ^b   Ahn, Chul Woo ^b   Lim, Sung Kil ^b   Lee, Hyun Chul ^b   Cha, Bong Soo ^b  

^a Inha University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c CHA University   (South Korea)

^d Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BODY MASS; CALCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE COURSE; DISEASE DURATION; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAL; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PREDICTION; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; BIOLOGICAL MARKERS; C-PEPTIDE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; REGRESSION ANALYSIS; STATISTICAL DISTRIBUTIONS;

EID: 33750268246     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02249     Document Type: Article

References (24)

1. Hovorka R, Chassin L, Luzio SD, Playle R & Owens DR. Pancreatic β-cell responsiveness during meal tolerance test: model assessment in normal subjects and subjects with newly diagnosed noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1998 83 744-750.
2. UK Prospective Diabetes Study Group. UK prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995 44 1249-1258.
3. Borona E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC & Muggeo M. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes. Diabetes Care 2001 24 2023-2029.
4. Avignon A, Radauceanu A & Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997 20 1822-1826.
5. Bouma M, Dekker JH de Sonnaville JJ, Van der Does FE, de Vries H, Kriegsman DM, Kostense PJ, Heine RJ & van Eijk JT. How valid is fasting plasma glucose as a parameter of glycemic control in noninsulin-using patients with type 2 diabetes? Diabetes Care 2004 22 904-907.
6. Verges B. The impact of regulation of postprandial glucose in practice. Diabetes and Metabolism 1999 25 22-25.
7. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM & Evans AT. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. New England Journal of Medicine 1995 333 1237-1241.
8. Feinglos MN, Thacker CH, English J, Bethel MA & Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997 20 1539-1542.
9. Albarrak Al, Luzio SD, Chassin LJ, Playle RA, Owens DR & Hovorka. R. Associations of glucose control with insulin sensitivity and pancreatic β-cell responsiveness in newly presenting type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2002 87 198-203.
10. Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, Awata T & Katayama S. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Research and Clinical Practice 2005 68 250-257.
11. Vichayanrat A, Ploybutr S, Tunlakit M & Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Research and Clinical Practice 2002 55 99-103.
12. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW Mathisen AL & Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 23 1605-1611.
13. Fonseca V, Rosenstock J, Patwardhan R & Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000 283 1695-1702.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
15. Haupt E, Haupt A, Herrmann R, Benecke-Timp A, Vogel H & Walter C. The KID Study V: the natural history of type 2 diabetes in younger patients still practicing a profession. Heterogeneity of basal and reactive C-peptide levels in relation to BMI, duration of disease, age and HbA1c. Experimental and Clinical Endocrinology and Diabetes 1999 107 236-243.
16. Palmer JP, Fleming GA, Greenbaum Q, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS & Steffes MW C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function. Report of an ADA workshop, 21-22 october 2001. Diabetes 2004 53 250-264.
17. Schatz D, Cuthbertson D, Atkinson M, Saizler MC, Winter W. Muir A, Silverstein J, Cook R, Maclaren N, She JX, Greenbaum C & Krischer J. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes meltitus - a new surrogate measure of non-progression? Pediatric Diabetes 2004 5 72-79.
18. The DCCT Research Group. Effects of age, duration and treatment of insuhn-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). Journal of Clinical Endocrinology and Metabolism 1997 65 30-36.
19. DeFronzo RA & Prato SD. Insulin resistance and diabetes mellitus. Journal of Diabetes and its Complications 1996 10 243-245.
20. DeFronzo RA & Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991 14 173-194.
21. Kruszynska YT & Olefsky JM. Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. Journal of Investigative Medicine 1996 44 413-428.
22. Porte D, Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991 40 166-180.
23. Kahn SE. The importance of β-cell failure in the development and progression of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2001 86 4047-4058.
24. Torrens JI, Skurnick J, Davidow AL, Korenman SG, Santoro N, Soto-Greene M, Lasser N & Weiss G. Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN). Diabetes care 2004 27 354-361.